SM
RVNC

Sabby Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Sabby Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-339
Closed -$461K – 339
2016
Q2 		$461K Buy
339
+37
+12% +$654 0.02% 214
2016
Q1 		$527K Sell
302
-532
-64% -$10.8K 0.03% 206
2015
Q4 		$2.85M Buy
834
+19
+2% +$659 0.16% 98
2015
Q3 		$2.42M Buy
815
+201
+33% +$6.11K 0.1% 136
2015
Q2 		$1.96M Buy
+614
New +$15.8K 0.07% 163

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NHG
NQ HCIF GP Raleigh, North Carolina $50.2M AUM 45.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management's RVNC Position: Q2 2015 in Review

Sabby Management sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2015, closing a stake of 23,065 shares — an estimated $593K sold.

Sabby Management first reported a position in RVNC in Q2 2014 and held it in 4 quarters. The position peaked at $2.29M in Q2 2014. 88 funds tracked by Wall St. Rank hold RVNC as of Q2 2015.

  • Sabby Management reported no remaining Revance Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • Sabby Management sold 23,065 Revance Therapeutics, Inc. shares in Q2 2015, an estimated $593K.
  • Sabby Management first reported a position in Revance Therapeutics, Inc. in Q2 2014 and held it in 4 quarters.
  • Sabby Management's Revance Therapeutics, Inc. position peaked at $2.29M in Q2 2014.
  • 88 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2015.

Based on Sabby Management's 13F filing for Q2 2015, filed 14 Aug 2015.